Item | Price | Qty | Total | |
---|---|---|---|---|
de Jesus BB, Schneeberger K, Vera E, Tegera A, Harley CB, Blasco MA. Aging Cell. 2011 August; 10(4): 604-621.
This animal study looked at the effects of TA-65® and confirmed
their mechanism of action, long-term effects, and safety.
Study Model: To confirm mechanism of action (through Telomerase
Activation), mice that were haploinsufficient for the telomerase RNA Terc gene
(Terc -/+) were treated, as well as mice that were bred for telomerase
deficiency (Terc -/-). Both groups were confirmed to possess critically short
telomeres at the study start. It was proposed that if the mechanism of action
was indeed the activation of telomerase, only the group with a functioning
Terc gene should respond to treatment; the telomerase-deficient group should
experience no treatment effect.
The study tracked telomere length and other health indicators in the treatment
groups and control group. No adverse incidents were seen.
Findings, Method of Action: Significant effects were seen in the Terc +/-
group while no effects were seen in the Terc -/- group, indicating
that TA-65® does indeed work through the Telomerase-Activation
pathway.
Findings, Health Effects: In telomerase-proficient
mice, TA-65® decreased the percentage of short telomeres and
decreased the incidence of DNA compromise typically associated with a high
percentage of short telomeres. TA-65® appeared to demonstrate a
“preference” for activating telomerase in cells with the shortest
telomeres, as indicated by a pronounced decrease in very short telomeres. This
overall support for whole health on a cellular DNA level helps to explain the
other key findings. TA-65® was found to influence several
biomarkers. Notably, in the telomerase-proficient TA-65® treated
group, researchers confirmed significant support for:
TA-65® did not impact the mean or maximum longevity of the
telomerase-proficient treatment group, but it did significantly influence the
functional healthspan.
Findings, Safety: No adverse events were seen,
and TA-65® did not cause any unregulated cell growth. This
supports TA-65®‘s previously noted safe, transient effects
on Telomerase Activation in healthy cells.